Analyzing the Future of Non-Cystic Fibrosis Bronchiectasis Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the non-cystic fibrosis bronchiectasis market right now?
In recent times, the market size for non-cystic fibrosis bronchiectasis has seen significant growth. It is forecasted to increase from $3.5 billion in 2024 to $3.74 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. This past growth can be credited to factors such as the rise in incidence and prevalence, advancements in diagnostic methods, an aging population, government backing and funding, an enhanced healthcare infrastructure, greater awareness of diagnosis, a growing older population, and environmental exposure.
How fast Is the non-cystic fibrosis bronchiectasis market expected to grow, and what’s its future value?
The market for non-cystic fibrosis bronchiectasis is predicted to undergo considerable growth in the coming years, with expectations to reach $4.82 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth include the progression in personalized medicine and the introduction of new biomarkers, along with increased funding for respiratory medicine and ongoing research and development efforts. Other influences include public health drives, the worldwide increase in the elderly population, and the pursuit of targeted therapies. The forecast period will witness significant trends such as digital health tools, emphasis on targeted therapies, implementation of AI and machine learning, a transition towards home-based care, patient-focused strategies and the upsurge of mobile health (mHealth) solutions.
Get your non-cystic fibrosis bronchiectasis market report here!
What are the leading drivers of growth in the non-cystic fibrosis bronchiectasis market?
The non-cystic fibrosis bronchiectasis market is anticipated to grow due to the increasing occurrence of respiratory conditions. Any disruption in the respiratory system, including the lungs, affects overall respiration and breathing. Pollution, both indoor irritants like tobacco smoke and outside contaminants, is the main contributor to the rising spread of these respiratory disorders. The escalating prevalence of respiratory infections provides opportunities for progress in the comprehension, diagnosis, and handling of non-cystic fibrosis bronchiectasis through specialized interventions and public health initiatives. For example, in June 2023, the UK’s Office for Health Improvement and Disparities reported a total of 4,622 notifications of Group A Streptococcus bacteria, otherwise known as scarlet fever, from the 37th to the 46th week in England’s 2022-2023 season, with 851 alerts alone in week 46. In comparison, this is a shocking increase from the previous five years’ average of 1,294 alerts (ranging from 258 to 2,008) for the same weeks. Consequently, the growth of the non-cystic fibrosis bronchiectasis market will be driven by the escalating occurrence of respiratory conditions.
What are the key segments defining the non-cystic fibrosis bronchiectasis market?
The non-cystic fibrosis bronchiectasis market covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types
2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments
3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray
4) By Lung Function: Spirometry, Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture
6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
Who are the key players steering the development of the non-cystic fibrosis bronchiectasis market?
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy’s Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc
How are evolving market trends shaping non-cystic fibrosis bronchiectasis Strategies?
Leading firms in the non-cystic fibrosis bronchiectasis market are directing their efforts towards personalized healthcare procedures, such as nebulization solutions, to enhance drug distribution efficiency and patient adherence. Nebulization solutions apply cutting-edge technology to accurately and effectively administer respiratory medicine, thereby improving patient adherence and treatment results. For example, in April 2022, Zambon S.P.A, a multinational pharmaceutical corporation based in Italy, was given a US FDA designation for CMS I-neb therapy for individuals with non-cystic fibrosis bronchiectasis (NCFB). CMS I-net is an experimental therapy designed to be a potentially first-in-class inhaled treatment for adult patients with NCFB that is colonized with P. aeruginosa. NCFB is a chronic, ongoing, and irreversible lung disorder. This landmark designation underscores the registration path for CMS I-neb in NCFB and may hasten its development and review.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17209
Which regions are most influential in expanding the non-cystic fibrosis bronchiectasis market?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2023. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Bronchoscope Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/bronchoscope-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2024
Polycystic Ovarian Syndrome Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
